Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: William B. Kohn who wrote (29587)	12/13/1999 2:22:00 PM
From: celeryroot.com	Respond to of 32384

the idea is to get it approved for anything

To: William B. Kohn who wrote (29587)	12/13/1999 3:02:00 PM
From: Cheryl Galt	Read Replies (2) \| Respond to of 32384

Plenty of sugar! Once approved and on the market, a drug seems to enter many additional studies at various university cancer centers, exploring new indications and combinations -- at no expense to the company except for perhaps supplying the drug. I'm especially looking forward to seeing Targretin tested in combinations. Also, individual doctors will soon be free to try Targretin on various cancer patients who have become resistant to other drugs, or for whom other chemo is too toxic. -------------------- RE the turn-down for early-stage (7/5 with 4 abstentions): My guess is that the objectors and abstainers wanted a larger sample size. In the open-label early-stage study, there were only 28 patients in the 300 mg/m2/day initial dosage level that was submitted for NDA approval. (2/28 patients had complete remission. 13 others had a partial response of at least 50% remission.) Any other ideas anyone??